Omada Health, Inc. (OMDA) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Omada Health, Inc. (OMDA) stock forecast summary
Our AI ranks Omada Health, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Omada Health, Inc. is a small-cap company with a market capitalization of $1.12B. It ranks number 7 by market capitalization among the 10 Services-Health Services issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for OMDA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.6%, strong sell < -1.7% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, OMDA included.
Follow OMDA freeOMDA price chart and AI forecast
How OMDA ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Omada Health, Inc. (OMDA) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Health Services peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
Valuation & Market
| Metric | OMDA | Rank |
|---|---|---|
| Market Cap | $1.12B | 7/10 |
| P/B Ratio | 4.43x | 3/9 |
| EPS | $-0.03 | – |
| Book Value/Share | $4.13 | – |
| Revenue/Share | $5.96 | – |
| FCF/Share | $0.37 | – |
Profitability & Margins
| Metric | OMDA | Rank |
|---|---|---|
| ROIC | -3.5% | 6/11 |
| Gross Margin | 66.6% | 2/8 |
| Operating Margin | -2.4% | 6/12 |
| EBT Margin | -1.4% | 6/12 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | OMDA | Rank |
|---|---|---|
| Current Ratio | 3.91x | 2/11 |
| Quick Ratio | 3.85x | – |
| D/E Ratio | 0.30x | 10/12 |
| Financial Leverage | 1.30x | 10/12 |
| Interest Coverage | 295.8x | 1/11 |
| Working Capital | $219M | 2/11 |
Cash Flow
| Metric | OMDA | Rank |
|---|---|---|
| Operating Cash Flow | $24M | 6/13 |
| Free Cash Flow | $23M | 5/9 |
| Capital Spending | -$960K | 2/9 |
| FCF/Sales | 6.2% | 3/9 |
| CapEx/Sales | 0.3% | 9/9 |
Operational Efficiency
| Metric | OMDA | Rank |
|---|---|---|
| Asset Turnover | 1.11x | 6/11 |
| Receivables Turnover | 6.5x | 5/9 |
| Inventory Turnover | 29.5x | – |
| Fixed Assets Turnover | 40.1x | 3/10 |
| Days Sales Outstanding | 57 days | 5/9 |
| Days Inventory | 12 days | – |
| Payables Period | 35 days | – |
| Cash Conversion Cycle | 34 days | – |
Income Statement
| Metric | OMDA | Rank |
|---|---|---|
| Total Revenue | $364M | 8/11 |
| Operating Income | -$8M | 8/13 |
| R&D Expense | $58M | – |
| SG&A Expense | $235M | 4/11 |
| Cost of Goods Sold | $122M | 5/8 |
Dividend & Shareholder Information
| Metric | OMDA | Rank |
|---|---|---|
| Shares Outstanding | 61M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $295M | 89.8% of assets |
| Cash & Short-term Investments | $222M | 67.5% of assets |
| Accounts Receivable | $57M | 17.2% of assets |
| Inventory | $4M | 1.3% of assets |
| Total Liabilities | $75M | 23.0% of assets |
| Short-term Debt | $64M | 19.4% of assets |
OMDA quarterly financials and insider trading
Omada Health, Inc. (OMDA) industry peers
Companies classified under the same SEC industry code as Omada Health, Inc. (Services-Health Services): 13 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| OMDA Omada Health, Inc. | ▲ | $1.12B |
| LFST Lifestance Health Group, Inc. | ▲ | $4.71B |
| PRVA Privia Health Group, Inc. | ▼ | $2.77B |
| WGS Genedx Holdings Corp. | ▲ | $1.94B |
| PNTG Pennant Group, Inc. | ▶ | $1.40B |
| USPH U S Physical Therapy Inc /Nv | ▶ | $1.27B |
| INNV Innovage Holding Corp. | ▲ | $1.23B |
| SRTA Strata Critical Medical, Inc. | ▲ | $394M |
| EUDA Euda Health Holdings Ltd | ▶ | $32M |
| DCGO Docgo Inc. | ▲ | $30M |
| ATPC Agape Atp Corp | ▼ | N/A |
| PIII P3 Health Partners Inc. | ▲ | N/A |
| VSEE Vsee Health, Inc. | ▼ | N/A |
Where OMDA sits on the market map
Omada Health, Inc. (OMDA) stock news
Loading...
Omada Health, Inc. (OMDA) stock forecast FAQ
What is the Omada Health, Inc. (OMDA) stock forecast?
Our AI ranks Omada Health, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Omada Health, Inc. stock predictions?
A per-ticker accuracy statistic for OMDA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Omada Health, Inc. forecasts updated?
Omada Health, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Omada Health, Inc.'s industry peers?
13 issuers in our coverage, OMDA included, share the SEC industry code Services-Health Services. The largest are: Lifestance Health Group, Inc. (LFST), Privia Health Group, Inc. (PRVA), Genedx Holdings Corp. (WGS), Pennant Group, Inc. (PNTG), U S Physical Therapy Inc /Nv (USPH), Innovage Holding Corp. (INNV).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.